下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Pure Extracts Technologies Corp. Closes Special Warrant Offering and Debt Settlement and Grants Options
Pure Extracts Technologies Corp.关闭特别认股权证发售和债务清偿以及授予选择权

GlobeNewswire ·  {{timeTz}}

Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States.

不得向美国新闻通讯社分发,或在美国境内或境内直接或间接地全部或部分直接或间接发布、出版、分发或传播。

VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. ("Pure Extracts" or the "Company") (CSE: PULL) (XFRA: A2QJAJ) is pleased to announce that it has completed a non-brokered private placement offering (the "Offering") of special warrants (each, a "Special Warrant"). In connection with the Offering, the Company issued an aggregate of 5,937,001 Special Warrants at a price of $0.075 per Special Warrant, for aggregate gross proceeds of $445,275. The Company also closed its offer to settle an aggregate of $206,433in debt owed to certain creditors (the "Debt Settlement") in exchange for units (the "Debt Units"), which Debt Units have the same terms as the units to be issued on conversion of the Special Warrants, all as further described below.

温哥华,不列颠哥伦比亚省,2022年3月8日(环球通讯社)纯萃取技术公司("纯提取物“或”公司“)(CSE:Pull)(XFRA:A2QJAJ)很高兴地宣布,它已经完成了一项非经纪私募发行(”供奉)份特别认股权证(每份,一份)特别授权“)。就是次发行,本公司发行了合共5,937,001份特别认股权证,每份特别认股权证的价格为0.075元,总收益为445,275元。本公司亦截止要约,以清偿欠若干债权人的合共206,433元债务(”清偿债务“)以换取单位(”债务单位“),哪些债务单位的条款与将于转换特别认股权证时发行的单位相同,详情如下所述。

Special Warrant Offering

特别认股权证发售

The Special Warrants will automatically convert to units (the "Units") upon the earlier of the receipt for a prospectus qualifying the distribution of the Units or four months and a day from the closing date of the Offering. Each Unit will be comprised of one common share of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder to acquire one Common Share (a "Warrant Share") at an exercise price of $0.15 per Warrant Share for a period of 24 months following the deemed exercise date of the Special Warrants.

特别认股权证将自动转换为单位(“单位)自收到有资格分派单位的招股说明书之日起或自招股结束日起计四个月零一日起计。每个单位将由一股公司普通股组成(每股一股)普通股)和一份普通股认购权证(每份搜查令“)。每份认股权证将使持有人有权收购一股普通股(A)。”认股权证股份“),行使价为每股认股权证股份0.15美元,于认股权证被视为行使日期后24个月内行使。

Finder's fees of $14,169 cash and 188,930 finder's warrants (each a "Finder's Warrant") were paid and issued in conjunction with the Offering. Each Finder's Warrant entitles the holder thereof to purchase one common share of the Company (each a "Finder's Warrant Share") at an exercise price of $0.15 per Finder's Warrant Share until March 7, 2024.

拾得人手续费14,169美元现金和188,930张拾得人认股权证(各一份)寻获人的授权书“)与发行同时支付及发行。每份寻获人认股权证持有人有权购买一股本公司普通股(每股一股)。”发现者认股权证股份“),行使价为每股发现者认股权证0.15美元,直至2024年3月7日。

All securities issued under the Offering will be subject to a statutory 4-month plus one day hold period, which expires on July 8, 2022, in accordance with applicable Canadian securities laws.

根据适用的加拿大证券法,根据此次发行发行的所有证券都将受到法定的4个月加1天的持有期的约束,该持有期将于2022年7月8日到期。

The Company intends to use net proceeds from the Offering primarily for the build-out of the Company's Michigan, USA extraction facility and for general working capital.

该公司打算将此次发售的净收益主要用于扩建公司在美国密歇根州的开采设施和一般营运资金。

The Company may elect to qualify the distribution of the Common Shares and Warrants issuable upon exercise of the Special Warrants by way of a supplement ("Prospectus Supplement") to the Company's short form base shelf prospectus dated March 4, 2021. The Company is under no obligation to file a Prospectus Supplement, and may elect to do so in its sole discretion. The Special Warrants and Warrants will not be listed on any stock exchange or over‐the‐counter market.

本公司可选择对行使特别认股权证时可发行的普通股及认股权证的分派给予资格,作为补充(“招股说明书副刊“)于本公司日期为2021年3月4日的简明基础架子招股说明书。本公司并无义务提交招股章程副刊,并可全权酌情选择提交。该等特别认股权证及认股权证不会在任何证券交易所或场外交易市场上市。

Three insiders of the Company subscribed for a total of 656,666 Special Warrants in connection with the Offering. Such participation is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("MI 61-101"). The transaction was exempt from the formal valuation and minority shareholder approval requirements of MI 61-101, as neither the fair market value of any securities issued to nor the consideration paid by such persons exceeded 25% of the Company's market capitalization.

本公司三名内部人士认购了与是次发售有关的合共656,666份特别认股权证。这种参与被认为是多边文书61-101所定义的“关联方交易”(“米其林61-101该交易获豁免遵守MI 61-101的正式估值及小股东批准要求,因为向该等人士发行的任何证券的公平市值及支付的代价均不超过本公司市值的25%。

Debt Settlement

清偿债务

Pursuant to the Debt Settlement, the Company has issued 2,752,448 Debt Units for a total debt settlement of $206,433. Debt settled by insiders of the Company accounted for 1,035,073 Debt Units representing approximately $77,630 of the Debt Settlement. Such participation constituted a "related party transaction" within MI 61-101. The issuance to the insiders is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the securities issued, or the consideration paid by such persons, did not exceed 25% of the Company's market capitalization.

根据债务清偿协议,公司发行了2,752,448个债务单位,债务清偿总额为206,433美元。公司内部人士结清的债务占1035,073个债务单位,约占债务结算额的77,630美元。这种参与构成了MI 61-101范围内的“关联方交易”。由于所发行证券的公平市值或该等人士支付的代价不超过本公司市值的25%,向内部人士发行的证券获豁免遵守MI 61-101的正式估值及小股东批准要求。

All securities issued under the Debt Settlement will be subject to a statutory 4-month plus one day hold period, which expires on July 8, 2022, in accordance with applicable Canadian securities laws.

根据适用的加拿大证券法,根据债务解决方案发行的所有证券都将受到法定的4个月加1天的持有期的约束,该期限将于2022年7月8日到期。

Option Grant

期权授予

The Company also announces that it has granted incentive stock options to certain directors, officers, and consultants of the Company to purchase up to 4,225,000 common shares in the capital of the Company pursuant to the Company's stock option plan. The options are exercisable on or before March 8, 2025 at an exercise price of $0.075 per share. The grant of options is subject to regulatory approval.

本公司还宣布,它已向本公司的某些董事、高级管理人员和顾问授予激励性股票期权,以便根据本公司的股票期权计划购买最多4225,000股本公司股本中的普通股。这些期权可在2025年3月8日或之前行使,行权价为每股0.075美元。期权的授予还有待监管部门的批准。

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.

本新闻稿中提及的证券没有、也不会根据修订后的1933年“美国证券法”注册,如果没有在美国注册或未获得美国注册要求的适用豁免,不得在美国境内或向美国人提供或出售证券,或为美国人的账户或利益提供或出售证券。本新闻稿不构成出售证券的要约,也不招揽购买任何证券的要约。

About the Company

关于本公司

The Company holds a Standard Processing License under the Cannabis Act granted by Health Canada on September 25, 2020 to Pure Extracts Manufacturing Corp., the Company's wholly-owned subsidiary. The Company is undertaking the operations of toll processing, white labelling, and developing its own private label of products incorporating its full spectrum THC and CBD based extracted oils. Additionally, the Company is presently expanding its business to include functional mushrooms extraction by working on functional mushroom extraction processes compatible with its existing infrastructure. The Company has a fully built C02 extraction facility built to European Union GMP standards, and intends to seek EU GMP certification of its operations allowing it to export its products for sale in Europe where such products are legal.

本公司持有《标准加工许可证》大麻法案由加拿大卫生部于2020年9月25日授予该公司的全资子公司纯萃取物制造公司。该公司正在进行收费处理、贴上白色标签,并开发自己的自有标签,将其全谱THC和基于CBD的提取油结合在一起。此外,该公司目前正在扩大其业务,通过开发与其现有基础设施兼容的功能性蘑菇提取工艺,包括功能性蘑菇提取。该公司拥有一个按照欧盟GMP标准建造的完整的二氧化碳提取设施,并打算为其业务寻求欧盟GMP认证,使其能够将其产品出口到欧洲销售,因为欧洲的产品是合法的。

Find out more at: 

有关更多信息,请访问:

Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com

或联系方式:
纯提取投资者关系
电话:+16044932052
邮箱:info@pureExtract tcotp.com

ON BEHALF OF THE BOARD

我代表董事会

(signed) "Ben Nikolaevsky"
Ben Nikolaevsky
CEO and Director

(签名)“本·尼古拉耶夫斯基"
本·尼古拉耶夫斯基
首席执行官兼董事

This information release contains certain forward-looking information, including about the proposed use of proceeds of the Offering, the filing of a Prospectus Supplement, the receipt of CSE approval and the listing of the Warrants. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

本新闻稿包含某些前瞻性信息,包括有关发行所得资金的建议用途、招股说明书补充文件的提交、CSE批准的收到以及认股权证的上市情况。此类信息涉及已知和未知的风险、不确定性和其他因素,这些风险、不确定性和其他因素可能导致实际结果、业绩或成就与本文中的表述所暗示的大不相同,因此这些表述不应被解读为对未来业绩或结果的保证。所有前瞻性陈述均基于公司目前的信念以及公司所做的假设和目前可获得的信息以及其他因素。告诫读者不要过度依赖这些前瞻性陈述,这些陈述仅在本新闻稿发布之日发表。由于风险和不确定因素,包括该公司在其公开证券申报文件中确定的风险和不确定因素,实际事件可能与目前的预期大不相同。公司没有任何更新或修改任何前瞻性陈述的意图或义务,无论是由于新信息、未来事件或其他原因。


本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部